Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment

BMJ Open

Volumn 6, Issue 1, 2016, Pages

  Hill, Andrew ^a   Gotham, Dzintars ^b   Fortunak, Joseph ^c   Meldrum, Jonathan ^d   Erbacher, Isabelle ^b   Martin, Manuel ^b   Shoman, Haitham ^b   Levi, Jacob ^b   Powderly, William G ^e   Bower, Mark ^f  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c HOWARD UNIVERSITY   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e WASHINGTON UNIVERSITY   (United States)

^f CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CROSPOVIDONE; ERLOTINIB; IMATINIB; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG COST; DRUG FORMULATION; DRUG PACKAGING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CARCINOMA; LICENSING; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; NON SMALL CELL LUNG CANCER; PANCREAS CANCER; PATENT; PROFIT; SCALE UP; SHIPPING; THYROID CARCINOMA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COMMERCIAL PHENOMENA; DRUG INDUSTRY; ECONOMICS; GLOBAL HEALTH; NEOPLASMS;

ANTINEOPLASTIC AGENTS; COMMERCE; DRUG INDUSTRY; ERLOTINIB HYDROCHLORIDE; GLOBAL HEALTH; HUMANS; IMATINIB MESYLATE; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES;

EID: 84960412502     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009586     Document Type: Article

References (30)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2013. http://globocan.iarc.fr (accessed 1 Feb 2015).
2. Stewart BW, Wild CP, International Agency for Research on Cancer. World Cancer Report 2014. ISBN-13: 9789283204299
3. Economist Intelligence Unit. Breakaway: The global burden of cancer-challenges and opportunities. LIVESTRONG [online]. 2009:23. http://graphics.eiu.com/upload/eb/EIU-LIVESTRONG- Global-Cancer-Burden.pdf (accessed Jan 2016).
4. Arora A, Scholar E. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther2005;315:971-9.
5. European Medicines Agency. Search for 'imatinib'. http://www.ema. europa.eu/ema/(accessed 27 Apr 2015).
6. European Medicines Agency. Search for 'erlotinib'. http://www.ema. europa.eu/ema/(accessed 27 Apr 2015).
7. European Medicines Agency. Search for 'sorafenib'. http://www.ema. europa.eu/ema/(accessed 27 Apr 2015).
8. European Medicines Agency. Search for 'lapatinib'. http://www.ema. europa.eu/ema/(accessed 27 Apr 2015).
9. World Health Organization. 19th WHO Model List of Essential Medicines. 2015. http://www.who.int/medicines/publications/essentialmedicines/EML2015-8-May-15.pdf ?ua=1 (accessed 8 May 2015).
10. World Health Organization. WHO Model List of Essential Medicines 18th list. 2013. http://www.who.int/medicines/publications/essentialmedicines/18th-EML-Final-web-8Jul13.pdf (accessed 9 May 2015).
11. Statement by Youth Commission on Essential Medicines Policies. 2015. http://www.who.int/selection-medicines/committees/expert/20/reviews/open-session-YCEMP-statement-18-apr-15.pdf?ua=1 (accessed 8 May 2015).
12. World Health Organization. Criteria for selection of essential medicines. http://archives.who.int/eml/expcom/children/Items/Criteria-selectionEMC.pdf (accessed 8 May 2015).
13. Bazargani YT, de Boer A, Schellens JHM, et al. Selection of oncology medicines in low-and middle-income countries. Ann Oncol 2014;25:270-6.
14. de Lopes GL. Issues in access to cancer medications in low-and middle-income countries. Cancer Control 2013. http://cancercontrol. info/wp-content/uploads/2014/08/cc2013-24-26-Gilberto-NEW- 2013.pdf (accessed 9 May 2015).
15. National Institute for Health and Care Excellence. Sorafenib for treatment of advanced renal cell carcinoma. 2009. https://www.nice. org.uk/guidance/ta178 (accessed 9 May 2015).
16. Palmer DH, Hussain SA, Smith AJ, et al. Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. Br J Cancer 2013; 109:888-90.
17. Ma YT, Palmer DH. Impact of restricting access to high-cost medications for hepatocellular carcinoma. Expert Rev Pharmacoecon Outcomes Res 2012;12:465-73.
18. James N, Pascoe J, Zachariah A, et al. Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors. Clin Oncol 2009;21:610-16.
19. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-42.
20. MSF Access Campaign. Untangling the web of antiretroviral price reductions. 17th edn. 2014. http://msfaccess.org/content/untangling-web-antiretroviral-price-reductions-17th-edition-%E2% 80%93-july-2014 (accessed 9 May 2015).
21. AIDS Medicines and Diagnostics Service. Antiretroviral medicines in low-and middle-income countries: forecasts of global and regional demand for 2012-2015. 2013. http://apps.who.int/iris/bitstream/10665/83148/1/9789241505468-eng.pdf (accessed 3 Jun 2015).
22. Hill A, Khoo S, Fortunak J, et al. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis 2014;58:928-36.
23. Hill A, Gotham D, Cooke G, et al. Analysis of minimum target prices for production of entecavir to treat hepatitis B in high-and low-income countries. J Virus Erad 2015;1:103-10.
24. Export-Import data retrieved from http://www.infodriveindia.com by DG and MM on 1/3/2015.
25. Teva Canada Announces the Launch of (Pr)Teva-Erlotinib, a generic of (Pr)Tarceva®. MarketWatch. 2014. http://www.marketwatch.com/story/teva-canada-announces-the-launch-of-prteva-erlotinib-a-generic-of-prtarceva-2014-12-09 (accessed 27 Apr 2015).
26. Ahmed R. India's cipla cuts cancer drug prices by 75%. Wall Street Journal2012. http://www.wsj.com/articles/SB10001424052702304 743704577383720218258112 (accessed 31 Mar 2015).
27. Novartis. Novartis Annual Report. 2013. http://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2013-en.pdf (accessed 28 Sep 2015).
28. Hoen E't, Berger J, Calmy A, et al. Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J Int AIDS Soc 2011;14:15.
29. Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 2013;13:663-73.
30. Gokhale K. Merck to Bristol-Myers face more threats on India patents. Bloomberg. 2014. http://www.bloomberg.com/news/articles/2014-01-21/merck-to-bristol-myers-face-more-threats-on-india-patents (accessed 3 Jun 2015).